Impact of meningococcal C conjugate vaccine use in Australia

Medical Journal of Australia

Volumn 186, Issue 3, 2007, Pages 108-109

  Booy, Robert ^a   Jelfs, Jane ^a   El Bashir, Haitham ^b   Nissen, Michael D ^c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

AGE; AUSTRALIA; BACTERIAL MUTATION; BEHAVIOR MODIFICATION; CIGARETTE SMOKING; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; FINANCIAL MANAGEMENT; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH PROGRAM; HUMAN; IMMUNITY; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; INTERNATIONAL COOPERATION; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; POLITICS; RISK REDUCTION; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

EID: 33847306827     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb00828.x     Document Type: Editorial

References (12)

1. Patel MS. Australia's century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med J Aust 2007; 186: 136-141.
2. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994. Clin Infect Dis 1998; 26: 1159-1164.
3. Peltola H, Kataja JM, Makela PH. Shift in the age-distribution of meningococcal disease as predictor of an epidemic? Lancet 1982; 2: 595-597.
4. Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20 Suppl 1: S58-S67.
5. Kriz P, Kriz B, Svandova E, Musilek M. Antimeningococcal herd immunity in the Czech Republic - influence of an emerging clone, Neisseria meningitidis ET-15/37. Epidemiol Infect 1999; 123: 193-200.
6. Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2002. Commun Dis Intell 2003; 27: 196-208.
7. Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2005. Commun Dis Intell 2006; 30: 211-221.
8. De Greeff SC, de Melker H, Spanjaard L, et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006; 25: 79-80.
9. Maiden MC, Stuart JM; UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002; 359: 1829-1831.
10. Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 2002; 324: 809.
11. Skull SA, Butler JR, Robinson P, Carnie J. Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation. Int J Epidemiol 2001; 30: 571-578.
12. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ 2006; 332: 445-450.